

# Enabling personalized cancer care

oncobit

## Oncobit™ PM for personalized monitoring of melanoma

Oncobit™ PM BRAF V600 is composed of a digital PCR assay and software and allows the sensitive and specific detection of BRAFV600-mutant circulating tumor DNA in the plasma of melanoma patients. It provides a quantitative measure of five nucleotide changes within the BRAF gene affecting the amino acid Val600 including the absolute number of wildtype and mutated allele copies detected, as well as the mutant allele frequency.

- **Trueness demonstrated with certified reference material**
- **Fully validated with clinical samples according to European guidelines**
- **Linear over several orders of magnitude**
- **Cut-off (limit of blank) starting at 2 mutant molecules**
- **Quantification starting at 23 molecules**
- **Overall agreement of  $\geq 90\%$  in two clinical studies**
- **Unbiased and automatic data analysis and reporting with Oncobit™ PM Software**

Gene	Amino acid change	Assay cut-off*	Lower LoQ*	Upper LoQ*	Upcoming tests for
<i>BRAF</i>	p.Val600Arg	2.5	36.2	6221.9	<i>NRAS</i>
<i>BRAF</i>	p.Val600Glu	2.8	32.6	5594	<i>GNAQ</i>
<i>BRAF</i>	p.Val600Glu	2.7	37.7	5519.3	<i>GNA11</i>
<i>BRAF</i>	p.Val600Lys	2.8	23.2	4420.8	<i>SF3B1</i>
<i>BRAF</i>	p.Val600Asp	1.4	31.7	5753.4	<i>KRAS</i>

\*in molecules

Oncobit™ PM provides a rapid and robust quantification of circulating tumor DNA, enabling reliable monitoring of disease and therapy response, as well as early detection of disease progression to improve clinical trial evaluation and patient outcome.

### For more information, please contact

Dr. Claudia Scheckel, CEO  
claudia.scheckel@oncobit.com  
+41 78 850 07 87

Dr. Björn Biedermann, CBO  
bjoern.biedermann@oncobit.com  
+41 78 256 99 56

[www.oncobit.com](http://www.oncobit.com)



For professional use only. According to Directive 98/79/EC on *in vitro* diagnostics

